Structural heart disease articles

valve in valve

Valve-in-Valve with Self-Expanding Prosthesis: What Happens with Gradients at One Year?

Valve-in-Valve with Self-Expanding Prosthesis: What Happens with Gradients at One Year?

Degenerated surgical bioprostheses can be safely treated with CoreValve or CoreValve Evolut using the valve-in-valve procedure. Excellent 1-year clinical and hemodynamic outcomes were achieved in a non-selected regular population, i.e., “real-world” patients. The VIVA (Valve in Valve) registry, conducted at 23 sites, was a prospective study designed to systematically collect data from patients with degenerated

Pulmonary Hypertension: No Reason for TAVR Contraindication

In most severe aortic stenosis patients with pulmonary hypertension, transcatheter aortic valve replacement (TAVR) reduced pulmonary systolic pressure. There patients presented lower risk and lower all-cause mortality at short, median and long term. This data show that pulmonary hypertension should not be a TAVR contraindication. Pulmonary hypertension is common among TAVR patients. The most frequent

TAVI en bajo riesgo de moda en todas las publicaciones

Low-Risk TAVR Trending in All Papers

Transcatheter aortic valve replacement (TAVR) in low-risk patients with symptomatic severe aortic stenosis appears to be safe at one year. In a follow-up using computerized tomography (TC), hypoattenuated leaflet thickening was observed in a minority of patients, but it did not have a long-term hemodynamic impact. It should be noted that the management strategy for

Estenosis aórtica severa asintomática en añosos: ¿cuándo intervenir?

Safe for 80-Year-Olds. Should Nonagenarians be Withheld from TAVR?

According to this large global registry, mortality after transcatheter aortic valve replacement (TAVR) is twice as high in nonagenarians as against the “younger” group (90 patients. Additionally, risk scores cannot be trusted given that on the one hand they were designed for patients with planned surgery, and on the other hand, they included few patients

Es posible realizar MitraClip sin anestesia general

Outpatient Rhythm Monitoring After TAVR Could Save Us from Some Pacemakers?

Delayed high-grade block after transcatheter aortic valve replacement (TAVR) goes unnoticed in patients undergoing TAVR without prior conduction disorders because, most times, it takes place during hospitalization or immediately after the procedure. Right bundle branch block is a risk factor, but it has poor sensitivity for the prediction of high-grade blocks, and there may be

Lo más leído de mayo en solaci.org

The Most Read Articles of may in Interventional Cardiology

1- Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis This study especially designed to compare PCI vs. CABG in patients with left main coronary artery disease and low to intermediate Syntax score showed that 30-day and 3 -year outcomes of PCI with everolimus eluting stents vs CABG were consistent both in diabetic and non-diabetic

Post TAVR New Onset Left Bundle Branch Block at Long Term: Worth Our Attention?

After post TAVR mean 3-year follow-up, a new onset persistent left bundle branch block (LBBB) was not associated with higher mortality or hospitalization for cardiac failure according to this study to be published soon in J Am Coll Cardiol Intv. Nevertheless, LBBB was associated to higher risk of definite pacemaker and a negative impact in

Degeneración de las válvulas biológicas aórticas: un desafío cada vez más frecuente

Good News at 3 Years for “Valve-in-Valve”

In this new era, the paradigm to treat the whole spectrum of transcatheter aortic valve replacement (TAVR) patients has started to shift beyond risk. However, broadening the spectrum raises the question of durability, which is why any long-term TAVR outcomes in any context are welcome. This specific study studied TAVR durability in the treatment of

EuroPCR 2019 | Ultimo meta-análisis de TAVI, el espectro de tratamiento alcanza a todos los pacientes

EuroPCR 2019 | Most Recent TAVR Meta-Analysis: The Spectrum of Treatment Reaches All Patients

This new meta-analysis combines all randomized transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement trials and expands the scope of TAVR. Evidence across the range of risk studied supports a paradigm shift in patients with symptomatic severe aortic stenosis. The clinical superiority of TAVR compared with surgery has been demonstrated across the spectrum

EuroPCR 2019 | Leaflex: nuevo dispositivo para fracturar el calcio pre TAVI

EuroPCR 2019 | Leaflex: New Device for Pre-TAVR Calcium Fracture

Researchers behind this small study believe that fracturing the rigid calcium deposits on leaflets with this new device could delay the need for transcatheter aortic valve replacement (TAVR) or facilitate it. This device showed actual improvement of leaflet mobility together with mean gradient reduction. The Leaflex Performer system (Pi-Cardia) was used in 16 patients with

EuroPCR 2019 | La durabilidad del TAVI ofrece ciertas garantías a 8 y 10 años

EuroPCR 2019 | TAVR Durability Offers Certain Guarantees at 8 and 10 Years

It has been 3 years since EuroPCR 2016 and the presentation of the first data on possible transcatheter valve degeneration, which sparked fear regarding the possibility that transcatherter aortic valve replacement (TAVR) devices might degrade earlier than expected due to the pressure put on them to introduce them into the delivery catheter. At EuroPCR 2019,

Top